Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(25 sites)
United States
Cedars-Sinai Medical Center- Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California Sarah Cannon Research Institute at HealthONE, Denver, Colorado Florida Cancer Specialists, Orlando, Florida Florida Cancer Specialists, Sarasota, Florida Dana Farber Cancer Institute, Boston, Massachusetts Henry Ford Hospital, Detroit, Michigan Washington University, St Louis, Missouri John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey Columbia University Medical Center, New York, New York Memorial Sloan-Kettering Cancer Center, New York, New York The Ohio State University, Columbus, Ohio Sidney Kimmel Cancer Center - Thomas Jefferson, Philadelphia, Pennsylvania SCRI Oncology Partners, Nashville, Tennessee Tennessee Oncology, Nashville, Tennessee MDACC (MD Anderson Cancer Center), Houston, Texas Japan
Aichi Cancer Center Hospital, Aichi National Cancer Center Hospital East, Chiba Hokkaido University Hospital, Hokkaido Osaka University Hospital, Osaka Kindai University Hospital, Ōsaka-sayama Saitama Cancer Center, Saitama Shizuoka Cancer Center Hospital and Research Institute, Shizuoka National Cancer Center Hospital, Tokyo Cancer Institute Hospital of JFCR, Tokyo Showa University Hospital, Tokyo Last updated January 2026